research use only
Cat.No.S7758
| Related Targets | HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase |
|---|---|
| Other Alkylating Agent Inhibitors | Berberine (Umbellatine) MNNG (1-Methyl-3-nitro-1-nitrosoguanidine) |
|
In vitro |
DMSO
: 100 mg/mL
(131.26 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 761.84 | Formula | C39H43N3O11S |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 114899-77-3 | -- | Storage of Stock Solutions |
|
|
Read more about storage stability stock solution CAS number
| In vitro |
This compound can block EWS-FLI1 transcription factor activity, suppress Werner syndrome protein (WRN) expression and selectively sensitize Ewing sarcoma cells to the DNA-damaging effects of SN38. |
|---|---|
| In vivo |
In Tumor-Bearing Mice, trabectedin does not have an impact on the functional activity of MDSC but does significantly reduce the number of Ly6Chigh cells, the most suppressive subset. |
References |
|
(data from https://clinicaltrials.gov, updated on 2026-08-06)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07444619 | RECRUITING | Soft Tissue Sarcomas |
M.D. Anderson Cancer Center |
2026-06-12 | PHASE1 |
| NCT03138161 | RECRUITING | Advanced Soft Tissue Sarcoma; Metastatic Soft Tissue Sarcoma |
Sarcoma Oncology Research Center, LLC |
2017-04-13 | PHASE1; PHASE2 |
| NCT03886311 | RECRUITING | Sarcoma |
Sarcoma Oncology Research Center, LLC |
2019-05-15 | PHASE2 |
| NCT06524583 | RECRUITING | Leiomyosarcoma Uterus |
UNICANCER |
2025-01-27 | PHASE2 |
| NCT04535271 | RECRUITING | Leiomyosarcoma |
Sarcoma Oncology Research Center, LLC |
2021-09-09 | PHASE2 |
| NCT02275286 | RECRUITING | Liposarcoma, Myxoid; Sarcoma, Soft Tissue; Leiomyosarcoma; Liposarcoma; Pleomorphic Liposarcoma |
Grupo Espanol de Investigacion en Sarcomas |
2014-11 | PHASE1; PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.